OUR PLEDGE TO PATIENTS AND CAREGIVERS

ESCAPE is a clinical-stage biopharmaceutical company developing novel, precisely targeted products for the treatment of genetically defined neurodegenerative diseases.

Neurodegenerative diseases cause an unprecedented health and societal burden that is only expected to worsen as life expectancy increases. Currently approved treatments improve symptoms but do not modify the underlying disease. ESCAPE wants to develop disease modifying therapies. We intend to apply new understanding from the human genetics causing neurodegeneration to make a meaningful impact on patients suffering from neurodegenerative disorders.

ESCAPE is partnering with patients and caregivers to develop novel, oral, precision therapeutics. We have established a research program to support development of a targeted precision medicine for patients who have a specific genetic mutation in their LRRK2 gene (pronounced “lark-two”). Visit our dedicated website to see if you qualify for genetic testing and find detailed information on the research program at clinicaltrials.gov.

Learn about our research program and see if you qualify for genetic testing.

SEE IF YOU QUALIFY

See additional research program details at clinicaltrials.gov.

LRRK2 Genetic Testing Program

LRRK2 Natural History Study

If you are interested in receiving updates from us on any of our programs or for general inquiries, contact us.

Contact